Literature DB >> 21523388

Mathematical modeling to distinguish cell cycle arrest and cell killing in chemotherapeutic concentration response curves.

Salaheldin S Hamed1, Charles M Roth.   

Abstract

Concentration response experiments are utilized widely to characterize the response of tumor cell lines to chemotherapeutic drugs, but the assay methods are non-standardized and their analysis based on phenomenological equations. To provide a framework for better interpretation of these experiments, we have developed a mathematical model in which progression through the tumor cell cycle is inhibited by drug treatment via either cell cycle arrest or entrance into cell death pathways. By fitting concentration response data, preferably over a dynamic range, the contributions of these mechanisms can be delineated. The model was shown to fit well experimental data for three glioma cell lines treated with either carmustine or etoposide. In each cell line, the major mechanism of tumor cell inhibition was cell death for carmustine in contrast to cell cycle arrest for etoposide. The model also provides a possible interpretation for the acquired in vitro resistance of U87 cells to carmustine as an accelerated desensitization to cell killing effects. This approach will aid in understanding better the action of chemotherapeutic agents on tumor cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21523388     DOI: 10.1007/s10928-011-9199-z

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  30 in total

1.  A mathematical model of in vitro cancer cell growth and treatment with the antimitotic agent curacin A.

Authors:  F Kozusko; P Chen; S G Grant; B W Day; J C Panetta
Journal:  Math Biosci       Date:  2001-03       Impact factor: 2.144

Review 2.  Regulation of DNA repair throughout the cell cycle.

Authors:  Dana Branzei; Marco Foiani
Journal:  Nat Rev Mol Cell Biol       Date:  2008-02-20       Impact factor: 94.444

3.  Distinct mechanisms act in concert to mediate cell cycle arrest.

Authors:  Jared E Toettcher; Alexander Loewer; Gerard J Ostheimer; Michael B Yaffe; Bruce Tidor; Galit Lahav
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-12       Impact factor: 11.205

4.  A plausible model for the digital response of p53 to DNA damage.

Authors:  Lan Ma; John Wagner; John Jeremy Rice; Wenwei Hu; Arnold J Levine; Gustavo A Stolovitzky
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-26       Impact factor: 11.205

5.  Influence of in vivo growth on human glioma cell line gene expression: convergent profiles under orthotopic conditions.

Authors:  Kevin Camphausen; Benjamin Purow; Mary Sproull; Tamalee Scott; Tomoko Ozawa; Dennis F Deen; Philip J Tofilon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-31       Impact factor: 11.205

Review 6.  Targeting cell cycle and apoptosis for the treatment of human malignancies.

Authors:  Adrian M Senderowicz
Journal:  Curr Opin Cell Biol       Date:  2004-12       Impact factor: 8.382

7.  Integrating cell-cycle progression, drug penetration and energy metabolism to identify improved cancer therapeutic strategies.

Authors:  Raja Venkatasubramanian; Michael A Henson; Neil S Forbes
Journal:  J Theor Biol       Date:  2008-02-21       Impact factor: 2.691

Review 8.  Mechanisms of chemoresistance to alkylating agents in malignant glioma.

Authors:  Jann N Sarkaria; Gaspar J Kitange; C David James; Ruth Plummer; Hilary Calvert; Michael Weller; Wolfgang Wick
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

9.  Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks.

Authors:  Luís F Z Batista; Wynand P Roos; Markus Christmann; Carlos F M Menck; Bernd Kaina
Journal:  Cancer Res       Date:  2007-12-15       Impact factor: 12.701

10.  Mechanistic mathematical modelling of mercaptopurine effects on cell cycle of human acute lymphoblastic leukaemia cells.

Authors:  J C Panetta; W E Evans; M H Cheok
Journal:  Br J Cancer       Date:  2006-01-16       Impact factor: 7.640

View more
  7 in total

1.  Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells.

Authors:  Salaheldin S Hamed; Robert M Straubinger; William J Jusko
Journal:  Cancer Chemother Pharmacol       Date:  2013-07-09       Impact factor: 3.333

Review 2.  Assessment of non-linear combination effect terms for drug-drug interactions.

Authors:  Gilbert Koch; Johannes Schropp; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-09-16       Impact factor: 2.745

Review 3.  Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.

Authors:  Aman P Singh; Young G Shin; Dhaval K Shah
Journal:  Pharm Res       Date:  2015-02-11       Impact factor: 4.200

4.  Crosstalk between M2 macrophages and glioma stem cells.

Authors:  Leora M Nusblat; Molly J Carroll; Charles M Roth
Journal:  Cell Oncol (Dordr)       Date:  2017-06-22       Impact factor: 6.730

5.  Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia.

Authors:  Mohamed Elmeliegy; Jason Den Haese; Chetasi Talati; Meir Wetzler; William J Jusko
Journal:  Cancer Chemother Pharmacol       Date:  2020-08-03       Impact factor: 3.333

6.  Exposure time independent summary statistics for assessment of drug dependent cell line growth inhibition.

Authors:  Steffen Falgreen; Maria Bach Laursen; Julie Støve Bødker; Malene Krag Kjeldsen; Alexander Schmitz; Mette Nyegaard; Hans Erik Johnsen; Karen Dybkær; Martin Bøgsted
Journal:  BMC Bioinformatics       Date:  2014-06-05       Impact factor: 3.169

7.  Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells.

Authors:  Xin Miao; Gilbert Koch; Sihem Ait-Oudhia; Robert M Straubinger; William J Jusko
Journal:  Front Pharmacol       Date:  2016-11-15       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.